Talis Biomedical (NASDAQ:TLIS) Stock Price Down 1.7% – Here’s What Happened

Talis Biomedical Co. (NASDAQ:TLIS)’s share price traded down 1.7% on Friday . The stock traded as low as $1.72 and last traded at $1.72. 120 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 5,277 shares. The stock had previously closed at $1.75.

Talis Biomedical Price Performance

The firm has a market cap of $3.13 million, a price-to-earnings ratio of -0.06 and a beta of 1.57. The firm’s fifty day moving average is $2.08 and its 200-day moving average is $6.07.

Talis Biomedical (NASDAQ:TLIS) last released its earnings results on Monday, August 19th. The company reported ($4.86) earnings per share (EPS) for the quarter. Talis Biomedical had a negative net margin of 5,784.73% and a negative return on equity of 79.74%.

Insider Activity at Talis Biomedical

In related news, major shareholder Braden Michael Leonard acquired 13,167 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were purchased at an average price of $3.90 per share, for a total transaction of $51,351.30. Following the completion of the acquisition, the insider now owns 216,736 shares of the company’s stock, valued at approximately $845,270.40. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have bought a total of 15,033 shares of company stock worth $58,804 over the last quarter. Company insiders own 46.00% of the company’s stock.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.